Brief: Addex Regains Rights To GABAB Positive Allosteric Modulator Portfolio From Indivior
25/09/2026 07:26
BRIEF-Addex Regains Rights To GABAB Positive Allosteric Modulator Portfolio From Indivior Sept 25 (Reuters) - Addex Therapeutics Ltd ADXN.S:
ADDEX REGAINS RIGHTS TO GABAB POSITIVE ALLOSTERIC MODULATOR PORTFOLIO FROM INDIVIOR
ADDEX THERAPEUTICS - GAINS FULL OWNERSHIP OF RETURNED DEVELOPMENT CANDIDATE AND FREEDOM TO PURSUE NEW INDICATIONS
Source text: ID:nGNX9tvV7s
Further company coverage: ADXN.S
((Reuters.Briefs@thomsonreuters.com))
Recent news on Addex Therapeutics
See all newsBrief: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia
NASDAQ RESUMED AT 11:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:24 AM
Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses
Brief: Addex Therapeutics Q2 Operating Income CHF -645 Thousand